Savillex, LLC has completed its purchase of the Life Sciences Fluid Management business of Entegris, Inc., adding a portfolio of single-use bioprocessing and pharmaceutical manufacturing products to its high-purity fluid handling business.
Savillex, based in Eden Prairie, Minnesota, supplies high-purity fluid handling systems for life science and laboratory use worldwide. Entegris is based in Billerica, Massachusetts. Financial terms of the transaction were not disclosed.
Portfolio and capabilities
The acquired business brings products used in bioprocessing and pharmaceutical production, including Aramus and PE bags, single-use assemblies and components employed in discovery, clinical trials and commercial manufacturing. Savillex said the addition broadens its life sciences offerings with more high-performance single-use solutions.
The company also gains an experienced fluid management team and technologies focused on high-purity applications. According to Savillex, customers can expect a wider range of single-use products, more technical expertise and added capabilities for work that runs from early research through commercial production. The company said the combined strengths should help it deliver more value and help customers manage increasingly complex bioprocessing workflows.
Leadership comments
Eric Giesing, chief executive officer of Savillex, said the acquired business has established a strong position in high-purity single-use bioprocessing and that the Aramus line fits with Savillex’s existing Savillex, Containment and Bioprocessing offerings. He said the deal expands the company’s portfolio and allows it to offer a wider set of solutions to biopharmaceutical and pharmaceutical customers. Giesing also said Savillex is pleased to welcome the team and will keep investing in technologies intended to help customers speed the development and production of critical therapies.
Chris Bedi, general manager of Fluid Management at Savillex, said the transaction offers an opportunity to bring a broader set of high-value fluid management products to pharmaceutical and biopharmaceutical customers worldwide. He said the acquired portfolio complements Savillex’s existing capabilities and that the combined organization will continue to provide innovative solutions while expanding support for partners across drug development. Bedi said the company is eager to help customers bring new medicines to patients globally.
Strategic fit
Savillex said the acquisition supports its strategy of providing leading solutions for the life sciences market. The company said it remains committed to investment in innovation, quality and customer partnerships as it expands its portfolio to address the changing needs of biopharmaceutical and pharmaceutical manufacturers worldwide.
EC M&A of New York acted as financial advisor to Savillex, and Sidley Austin LLP of Chicago served as legal counsel.